

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BrainAurora Medical Technology Limited

脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6681)

VOLUNTARY ANNOUNCEMENT PUBLICATION OF RESEARCH RESULTS ON SELF-ADAPTIVE COGNITIVE REMEDIATION IN SCHIZOPHRENIA IN NPJ DIGITAL MEDICINE

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the investors informed of the latest update on the business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Group recently made significant scientific research achievements in the field of cognitive remediation in schizophrenia, the details of which are announced as follows:

I. PUBLICATION OF RESEARCH RESULTS IN NPJ DIGITAL MEDICINE

Recently, the clinical research results titled “Randomized trial of self-adaptive computerized cognitive remediation in schizophrenia” jointly conducted by the team of Professor Wang Gang (王刚) from Beijing Anding Hospital, Capital Medical University and the scientific research team of the Group were published in npj Digital Medicine (Impact Factor: 18.0, JCR Q1 Zone), a top international academic journal.

This study is a randomized, double-blind, and active-controlled clinical trial (ChiCTR2000040326) that enrolled a total of 90 patients with schizophrenia, who were randomized 1:1 into the self-adaptive difficulty training group (SAD, 41 cases completed the intervention) and the fixed-difficulty training group (FD, 31 cases completed the intervention), comparing the cognitive and clinical outcomes between the two groups at the 4-week intervention and 8-week follow-up. Participants in both groups completed training using the Group’s “Brain Function Information Management Platform Software System” (Class II medical device). Cognitive outcomes were assessed using Cognitive Index (CI) and the MATRICS Consensus Cognitive Battery (MCCB).

Key findings:

- (1) Faster and stronger cognitive improvement: Linear mixed-effects models showed that the self-adaptive group achieved significantly greater and faster improvements in the dimensions of attention and processing speed/agility ($P=0.02$), with faster improvement also observed in thinking.
- (2) Significant improvement in MCCB total score: The self-adaptive group performed significantly better than the control group on both the Continuous Performance Test-Identical Pairs (CPT-IP) and MCCB total score.
- (3) Significant improvement in positive symptoms: At the end of the 4-week training, the self-adaptive group showed a significant reduction in the positive symptom score of the Positive and Negative Syndrome Scale compared to that of the control group.
- (4) First demonstration of the “difficulty-performance coupling” mechanism: The study observed robust difficulty-performance coupling effects across five major cognitive domains: memory, attention, perception, agility, and thinking, indicating that dynamic difficulty calibration is a key active mechanism driving cognitive benefits.

The study conclusion noted that self-adaptive cognitive training can enhance and accelerate cognitive improvement in patients with schizophrenia, particularly in attention and processing speed, while also benefiting the improvement of positive symptoms. Difficulty-performance coupling may reflect the role of dynamic load calibration as a key therapeutic mechanism in digital cognitive training.

Reference: Ren Yp, Wang Ln, Lin S, et al. Randomized trial of self-adaptive computerized cognitive remediation in schizophrenia. npj Digital Medicine. 2026. DOI: 10.1038/s41746-026-02949-z.

II. SIGNIFICANCE OF THE ABOVE ACHIEVEMENTS TO THE GROUP

This study is the first randomized double-blind controlled trial to confirm that self-adaptive cognitive training can accelerate cognitive remediation in patients with schizophrenia, and is the first study to reveal “difficulty-performance coupling” as an active mechanism of digital therapeutics. The publication of such result in npj Digital Medicine with an impact factor of 18.0 indicates that the Group’s research in the field of digital therapeutics for psychiatric diseases has been highly recognized by a top international academic platform. The deep participation of the Group’s scientific research personnel fully reflects the ongoing deepening of the Group’s “industry-academia-research-medicine” integration model, thereby further expanding the Group’s evidence-based landscape for digital therapeutics.

The Board believes that the above achievements align with the Group’s long-term development strategy and should further consolidate the Group’s industry-leading position in the field of digital therapeutics for cognitive impairment, thereby creating long-term value for shareholders.

The contents of this announcement do not constitute a connected transaction or a notifiable transaction under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Tan Zheng
Chairman and Executive Director

Hong Kong, September 2, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Deng Feng, Mr. Yang Fan, and Ms. Wang Jingbo as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.